Literature DB >> 31266814

Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function.

Lingxiao Tan1, Kwang-Jin Cho2, Walaa E Kattan1, Christian M Garrido2, Yong Zhou1, Pratik Neupane3, Robert J Capon3, John F Hancock4.   

Abstract

The primary site for KRAS signaling is the inner leaflet of the plasma membrane (PM). We previously reported that oxanthroquinone G01 (G01) inhibited KRAS PM localization and blocked KRAS signaling. In this study, we identified acylpeptide hydrolase (APEH) as a molecular target of G01. APEH formed a stable complex with biotinylated G01, and the enzymatic activity of APEH was inhibited by G01. APEH knockdown caused profound mislocalization of KRAS and reduced clustering of KRAS that remained PM localized. APEH knockdown also disrupted the PM localization of phosphatidylserine (PtdSer), a lipid critical for KRAS PM binding and clustering. The mislocalization of KRAS was fully rescued by ectopic expression of APEH in knockdown cells. APEH knockdown disrupted the endocytic recycling of epidermal growth factor receptor and transferrin receptor, suggesting that abrogation of recycling endosome function was mechanistically linked to the loss of KRAS and PtdSer from the PM. APEH knockdown abrogated RAS-RAF-MAPK signaling in cells expressing the constitutively active (oncogenic) mutant of KRAS (KRASG12V), and selectively inhibited the proliferation of KRAS-transformed pancreatic cancer cells. Taken together, these results identify APEH as a novel drug target for a potential anti-KRAS therapeutic.
© 2019. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Acylpeptide hydrolase; KRAS; Oxanthroquinone; Plasma membrane; Recycling endosome; Sphingomyelin metabolism

Mesh:

Substances:

Year:  2019        PMID: 31266814      PMCID: PMC6703705          DOI: 10.1242/jcs.232132

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  55 in total

1.  Observing cell surface signaling domains using electron microscopy.

Authors:  Ian A Prior; Robert G Parton; John F Hancock
Journal:  Sci STKE       Date:  2003-04-08

2.  Enzymatic removal of oxidized protein aggregates from erythrocyte membranes.

Authors:  T Fujino; K Ando; M Beppu; K Kikugawa
Journal:  J Biochem       Date:  2000-06       Impact factor: 3.387

Review 3.  Ras proteins: different signals from different locations.

Authors:  John F Hancock
Journal:  Nat Rev Mol Cell Biol       Date:  2003-05       Impact factor: 94.444

Review 4.  Opinion: Searching for the elusive targets of farnesyltransferase inhibitors.

Authors:  Saïd M Sebti; Channing J Der
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

5.  Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase.

Authors:  T Fujino; K Watanabe; M Beppu; K Kikugawa; H Yasuda
Journal:  Biochim Biophys Acta       Date:  2000-03-16

6.  Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.

Authors:  Jian Yu; Sagarika Tiwari; Philipp Steiner; Lin Zhang
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

7.  Overexpression of oxidized protein hydrolase protects COS-7 cells from oxidative stress-induced inhibition of cell growth and survival.

Authors:  Kei Shimizu; Tomofumi Fujino; Ken Ando; Makio Hayakawa; Hideyo Yasuda; Kiyomi Kikugawa
Journal:  Biochem Biophys Res Commun       Date:  2003-05-16       Impact factor: 3.575

Review 8.  Rab GTPases coordinate endocytosis.

Authors:  J Somsel Rodman; A Wandinger-Ness
Journal:  J Cell Sci       Date:  2000-01       Impact factor: 5.285

9.  Compartmentalization of Ras proteins.

Authors:  I A Prior; J F Hancock
Journal:  J Cell Sci       Date:  2001-05       Impact factor: 5.285

10.  Direct visualization of Ras proteins in spatially distinct cell surface microdomains.

Authors:  Ian A Prior; Cornelia Muncke; Robert G Parton; John F Hancock
Journal:  J Cell Biol       Date:  2003-01-13       Impact factor: 10.539

View more
  8 in total

1.  The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure.

Authors:  Yong Zhou; Priyanka S Prakash; Hong Liang; Alemayehu A Gorfe; John F Hancock
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

2.  Cryo-EM structure of acylpeptide hydrolase reveals substrate selection by multimerization and a multi-state serine-protease triad.

Authors:  Anna J Kiss-Szemán; Pál Stráner; Imre Jákli; Naoki Hosogi; Veronika Harmat; Dóra K Menyhárd; András Perczel
Journal:  Chem Sci       Date:  2022-05-18       Impact factor: 9.969

3.  Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling.

Authors:  Christian M Garrido; Karen M Henkels; Kristen M Rehl; Hong Liang; Yong Zhou; Jordan U Gutterman; Kwang-Jin Cho
Journal:  Sci Rep       Date:  2020-06-04       Impact factor: 4.379

Review 4.  RAS: Striking at the Core of the Oncogenic Circuitry.

Authors:  Ryan C Gimple; Xiuxing Wang
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

5.  Differential Distribution and Activity Profile of Acylpeptide Hydrolase in the Rat Seminiferous Epithelium.

Authors:  Alejandra A Covarrubias; Erwin De la Fuente-Ortega; Gabriela Rossi; Ennio Cocca; Mosè Rossi; Gianna Palmieri; Floria C Pancetti
Journal:  Biomedicines       Date:  2022-07-04

6.  Approaches to inhibiting oncogenic K-Ras.

Authors:  Alemayehu A Gorfe; Kwang-Jin Cho
Journal:  Small GTPases       Date:  2019-08-22

Review 7.  Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity.

Authors:  Karen M Henkels; Kristen M Rehl; Kwang-Jin Cho
Journal:  Front Mol Biosci       Date:  2021-06-16

8.  Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression.

Authors:  Wang Jiang; Hao Li; Xiyu Liu; Jianping Zhang; Wuhu Zhang; Tianjiao Li; Liang Liu; Xianjun Yu
Journal:  Theranostics       Date:  2020-09-16       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.